St. Cloud Surgical Center is First ASC in U.S. to Utilize Xenex Germ-Zapping Robot to Disinfect Operating Rooms & Enhance Patient Safety more

4 cheap small cap stocks I’ve got my eye for Christmas more

Southern Biologics Network Established to Create Biologics Faster and Less Expensively more

Morningside Ministries at the Manor is the First Skilled Nursing Facility in Texas to Protect Residents with Xenex Germ-Zapping Robot more

RBA to cut rates in 2015: Still want to invest in term deposits? more

Can robots help stop the Ebola outbreak? more

Robots Help Fight Ebola more

South Florida Hospital Unveils Ebola-Zapping Robot more

Sonoma Valley Hospital uses robot to kill germs more

Robots go to war against Ebola more

New iTraumaCare CEO to pursue big growth more

UAB and SRI have plans to spinoff more success more

Launch of Galderma's new acne products more

iTraumaCare’s new CEO to help company secure new funding more

U.S. Air Force Hospital Langley Adds Xenex Ebola-Zapping Robot to Inventory more

Forthcoming Acne Treatment Made With Exclusive (And Sustainable) East Indian Sandalwood Oil more

Sonoma Valley Hospital Acquires Xenex Germ-Killing Robot to Enhance Patient Safety more

Robot fights germs at Sharp Chula Vista Medical Center more

Xenex updates protocols for germ-zapping robots in response to Ebola threat more

How do we get rid of the endotoxins? Birmingham's  has the solution more

Medical Device ® Positions New Leader for Next-Level Growth more

The Xenex robot at South Shore Hospital featured on an Xploration Earth more

Germ-zapping robot Gigi sets its sights on Ebola more

Morningside Ventures leads a Series B round for DNAtrix more

StemBioSys secures new research space at BioBridge Global more

Birmingham's Soluble Therapeutics acquires Seattle company Dilyx Biotechnology more

Company invents germ-zapping robot more

Xenex Congratulates Houston Cancer Hospital on “Environmental Services Department of the Year” Award from Health Facilities Management

3rd Consecutive Year Xenex Customer is Recognized

SAN ANTONIO--(BUSINESS WIRE)--Xenex Disinfection Services, the world leader in UV room disinfection systems for healthcare facilities, congratulates The University of Texas MD Anderson Cancer Center on its “2014 ES Department of the Year” award from Health Facilities Management (HFM) magazine and the Association for the Healthcare Environment. This is the third consecutive year that a Xenex customer has received the award. All three customers reported a reduction in healthcare associated infections (HAI) after the facility began using Xenex’s germ-zapping robots to eliminate the deadly pathogens that cause infections. The improved outcomes were one of the reasons each facility was chosen for the award.

MD Anderson began using Xenex devices in 2010 and has conducted several studies proving the efficacy of pulsed xenon UV light for room disinfection. The first study, published in Infection Control and Hospital Epidemiology (ICHE) in 2011, demonstrated that the Xenex system is 20 times more effective than traditional cleaning methods in destroying dangerous pathogens. A 2012 study demonstrated that Xenex’s pulsed xenon UV light robot is better than bleach for C.diff reduction. Use of the Xenex system (instead of bleach for rooms that housed patients with C.diff and VRE infections) resulted in a reduction in the number of patients contracting these infections.

“Congratulations to the MD Anderson Environmental Services and Infection Control teams on this well-deserved honor, which is a testament to their hard work and dedication to patient safety,” said Mark Stibich, PhD, co-founder and Chief Scientific Officer at Xenex. “Like MD Anderson, many Xenex customers are reporting significant reductions in hospital acquired infections when they use our robots to disinfect their facilities.”

Xenex’s germ-zapping robots use pulsed xenon UV light to quickly destroy viruses, bacteria, mold, fungus and bacterial spores in the patient environment without contact or chemicals. Its intense, broad-spectrum light penetrates the pathogens’ cell walls, causing the DNA to fuse instantly, and rendering them unable to reproduce or mutate. Its patented technology is 25,000 times more intense than mercury UV systems and enables Xenex germ-zapping robots to disinfect healthcare facilities in a fraction of the time it takes for mercury bulb devices to disinfect rooms. Uniquely designed for ease of use and portability, a hospital’s environmental services staff can operate the Xenex device without disrupting hospital operations or requiring the use of expensive chemicals. With a 5-10 minute cleaning cycle per room, the device disinfects dozens of rooms per day, including patient rooms, operating rooms (ORs), equipment rooms, emergency rooms, intensive care units (ICUs) and public areas. The only non-mercury UV room disinfection solution is provided by Xenex.

Geisinger Medical Center was the recipient of HFM’s “2013 ES Department of the Year” award. According to the magazine article, Geisinger implemented Xenex’s pulsed xenon UV light room disinfection system in 2012 and MRSA infection rates decreased 25 percent, with no other changes to established cleaning and disinfection protocols.

The University of Wisconsin (Madison) Hospital and Clinics received HFM’s “2012 ES Department of the Year” award. Tom Peck, UW Hospital's Environmental Services (ES) director, said use of the Xenex system was a key contributing factor in the hospital’s decrease in C.diff infections. Like Geisinger, UW and MD Anderson, many hospitals and VA facilities throughout the U.S. that use Xenex’s germ-zapping robots to disinfect patient care areas are reporting fewer infections.

Award coverage appears in the magazine’s September 2014 issue and online at www.hfmmagazine.com.

About Xenex Disinfection Services
Xenex's patented pulsed xenon UV room disinfection system is a pesticidal device used for the advanced cleaning of healthcare facilities. Due to its speed and ease of use, the Xenex system has proven to integrate smoothly into hospital cleaning operations. The Xenex mission is to eliminate harmful bacteria, viruses and spores that can cause hospital acquired infections in the patient environment, and to become the new standard method for disinfection in healthcare facilities worldwide. For more information, visit www.xenex.com.

Contacts
Xenex
Melinda Hart, 210-824-3433
melinda.hart@xenex.com

Source: http://www.businesswire.com

30 September 2014 back

Australian grown Indian Sandalwood timber attracts lucrative Asian markets more

DNATRIX ANNOUNCES TREATMENT OF FIRST PATIENT WITH DNX-2401 more

Targeted Technology raises more than $40 million more

Reducing Healthcare Associated Infections (HAIs): Not All UV Light is the Same more

Bluegrass Vascular Technologies Names Dr. Gabriele Niederauer President And CEO more

Three Birmingham companies recognized in PwC report more

Former Kinetic Concepts Inc. CEO to lead StemBioSys more

International dermatology company Galderma confirmed more

AUSTRALIAN Sandalwood producer TFS Corporation will supply oil more

San Antonio luring biotech firms with venture capital more

Biotech firm secures nearly $5 million in funding, is relocating to San Antonio more

Birmingham is on the front lines of medical research: take a look at this incredible biotech startup more

Germ-Zapping Robots Fight C. diff and MRSA at Mercy Health Saint Mary's more

Milford hospital enlists robots in war against infections more

Xenex Testifies About UV Room Disinfection Technology Effectiveness to U.S. House of Representatives more

Western Pa. hospitals test robot using ultraviolet rays to kill bacteria more

Xenex Demonstrates UV Room Cleaning System’s Effectiveness in Reducing Hospital Acquired Infections more

TFS flags record full-year profit more

Sweet scented sandalwood flavour of month more

House committee looks for new technology in Veterans Affairs hospitals more

FDA grants fast track status to drug DNX-2401 for recurrent Glioblastoma more

CEO shakeup at San Antonio biotech company StemBioSys more

First harvest to be completed in June more

BiO2 Medical Enrolls Subjects in the New U.S. FDA Early Feasibility Pilot Study for the Angel® Catheter more

San Antonio biotech firm readies skin treatment for distribution more

ViroXis Gets Approval To Initiate FDA Phase 2 Study For Molluscum Contagiosum more

Medical technologies conference announces speaker lineup more

Australian sandalwood sells for millions more

Sandalwood exports as good as gold more

Santalis Pharmaceuticals Signs Exclusive License Agreement with Global Pharmaceutical Company to Commercialize OTC Dermatology Products more

ViroXis Corporation Signs Exclusive License Agreement with Global Pharmaceutical Company to Commercialize an OTC Dermatology Product more

DNAtrix Awarded $10.8 Million Grant by the Cancer Prevention and Research Institute of Texas more

ViroXis Corporation Achieves Key Clinical Milestones more

There are growing concerns about the threat of an antibiotic crisis caused by the spread of drug-resistant superbugs. Those concerns could result in more